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Escitalopram in the Treatment of Malaysian 
Patients with Obsessive-compulsive Disorder
施用抗抑鬱藥草酸依他普侖治療馬來西亞病人的強迫症
A Hatim, JS Gill, ST Jambunathan, TH Yen, M Ariff, OM Lemming, MZ Azhar
Abstract
Objective: This post-hoc analysis examined the efficacy and tolerability of escitalopram in the prevention 
of relapse in Malaysian patients with obsessive-compulsive disorder.
Participants and Methods: In Malaysia, 47 patients with obsessive-compulsive disorder were treated 
with open-label escitalopram (10 mg or 20 mg/day) for 16 weeks, after which the 34 responders (Yale-
Brown Obsessive Compulsive Scale total decrease score, ≥ 25%) were randomised to placebo or 
escitalopram for 24 weeks, using a double-blind protocol.
Results: The primary efficacy analysis suggested a trend in favour of escitalopram treatment with 
respect to time to relapse (log-rank test, p = 0.07). A higher proportion of patients relapsed after placebo 
treatment (5 of 14, 36%) than with escitalopram treatment (2 of 20, 10%) [Fisher’s exact test, 2-sided; 
p = 0.10]. The risk of relapse was 4-fold higher for placebo than escitalopram treatment (p = 0.09). 
During the double-blind period, the proportion of patients reporting treatment-emergent adverse events 
was comparable in the 2 groups (10% in the escitalopram group vs. 14% in the placebo group); no serious 
events being reported.
Conclusions: This post-hoc subgroup analysis suggests that escitalopram is well tolerated in Malaysian 
patients with obsessive-compulsive disorder and appears to confer an advantage over placebo, in terms 
of time to relapse and other efficacy variables.
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摘要
目的：本分析旨在檢視草酸依他普侖在防止馬來西亞強迫症患者復發方面的療效，及患者對藥
物的耐受情況。
參與者與方法：以開放標籤方式對47位強迫症患者施用草酸依他普侖16星期（每日10 mg或
20 mg），繼而以雙盲法，對34位回應者（據耶魯布朗強迫症狀評量表，其症狀減輕總分
≥ 25%）隨機施用安慰劑或草酸依他普侖24星期。
結果：主要指標分析反映，以草酸依他普侖治療較有效，該組強迫症再發與用藥期相距的時間
比起安慰劑組的要長（log-rank檢驗，p = 0.07），而且安慰劑組強迫症復發的患者比例（14位
中的5位，36%）較草酸依他普侖組的（20位中的2位，10%）為高（Fisher’s確切概率，雙側
p = 0.10），復發的機會比草酸依他普侖組高四倍（p = 0.09）。在雙盲法用藥期，兩組患者報
告由治療引起不良事件的比例相若（用藥組10%比安慰劑組14%），亦無嚴重事故報告。
結論：本小組分析顯示，馬來西亞的強迫症患者對草酸依他普侖的耐藥情況良好，以強迫症再
發的時間及其他療效可變因子來看，該藥似乎比安慰劑佔優。
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Introduction
Escitalopram has been approved in many countries for 
the treatment of depression and anxiety disorders.1 Two 
recently published randomised controlled trials have 
demonstrated that it is also efficacious in the treatment of 
obsessive-compulsive disorder (OCD). One study was a 
24-week, placebo-controlled fixed-dose trial,2 and showed 
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for the first week, after which the dose could be increased to 
20 mg/day at a scheduled visit. Subsequently, the dose could 
be decreased to 10 mg/day according to the investigator’s 
judgement. After week 12, the dose was fixed. At the end 
of the 16-week open-label period, responders (those with ≥ 
25% decrease from baseline in total Yale-Brown Obsessive 
Compulsive Scale [Y-BOCS] score) were eligible for 
randomisation to escitalopram (fixed dose of 10 or 20 mg/
day), or placebo in a 1:1 ratio. Non-responders (withdrawn 
from the study) were treated at the investigator’s discretion.
 Patients randomised to placebo who were taking 
20 mg/day escitalopram from week 12 in the open-label 
period received 10 mg/day for the first week of the double-
blind period, and then placebo for the remainder of the 
study. Patients randomised to placebo who were taking 
10 mg/day escitalopram from week 12 in the open-label 
period received placebo for the double-blind period. 
Patients randomised to escitalopram continued on the dose 
they had received after week 12 in the open-label period. 
After completion of the study, there was a 1-week period 
of double-blind down-tapering, during which patients on
20 mg/day escitalopram received 10 mg/day, while patients 
on 10 mg/day escitalopram or placebo received only placebo.
 Throughout the 24-week double-blind period, the 
investigators evaluated relapse of symptoms; relapse was 
defined as either an increase in the Y-BOCS total score of ≥ 5 
points from the time of randomisation, or, an unsatisfactory 
treatment effect as judged by the investigator. Patients who 
relapsed were withdrawn from the study.
 Patients were enrolled from psychiatric practices, 
specialised clinical centres, psychiatric hospital departments, 
or general practices. Patients eligible for this study were 
outpatients between 18 and 65 years (extremes included). 
that escitalopram 20 mg/day was associated with an earlier 
onset and higher response rate, a higher remission rate, 
improved functioning, and better tolerance. A second trial, 
in patients with OCD by Fineberg et al,3 involved open-
label escitalopram treatment for 16 weeks, after which 
responders were randomised to placebo or escitalopram for 
24 weeks of double-blind treatment. This study, which was 
conducted in 14 countries including Malaysia, showed that 
escitalopram was well tolerated, and that improvements 
in symptoms observed during the open-label period were 
sustained by active drug treatment during the double-blind 
extension period.
 There is a paucity of data concerning the efficacy 
and adverse event (AE) profile of escitalopram treatment in 
Malaysian patients. Response to selective serotonin reuptake 
inhibitors (SSRIs) may be influenced by body weight, age, 
sex, and genetic makeup, and therefore can vary between 
individuals of different ethnic populations.4 To address this 
gap in knowledge, a subgroup analysis of the Malaysian 
patients who had participated in Fineberg et al’s3 study was 
performed. The results of this post-hoc subgroup analysis 
are also presented.
Methods
The design and conduct of this study has been described.3 
The study was approved by local ethics committees and all 
patients gave written informed consent. In Malaysia, the 
study was conducted at 4 centres.
 This was a relapse prevention study commencing with 
a 16-week open-label treatment period, followed by 24 weeks 
of double-blind, randomised treatment (Figure 1). During the 
open-label period patients received 10 mg/day escitalopram 
Relapse: Y-BOCS increase ≥ 5 
or lack of efficacy
Relapse: Y-BOCS increase ≥ 5 
or lack of efficacy
Escitalopram fixed dose 10 or 20 mg/day
Double-blind period
Placebo
Randomisation
Responders only
Open-label period
Week 0 Week 16 Week 40 Week 44
Figure 1. The study started with a 16-week open-label period followed by a 24-week, randomised, double-blind 
treatment period.
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They had to have a primary diagnosis of OCD according to 
Diagnostic and Statistical Manual of Mental Disorders 4th 
Edition, Text Revision5 without other primary psychiatric 
disorders or significant somatic morbidity, and with a Y-
BOCS total score ≥ 20.
 Efficacy and tolerability parameters were assessed at 
weeks 1 and 2, and then every 2 weeks during the open-label 
period. In the double-blind period, efficacy and tolerability 
parameters were assessed 2, 4, 6, 7, and 12 weeks after 
randomisation, and then every 4 weeks until their last dose 
of double-blind treatment.
 The prospectively defined primary analysis of efficacy 
was the time to relapse from the start date of double-blind 
treatment. Secondary efficacy parameters included: the 
proportion of relapsed patients and change in the total Y-
BOCS scores. Tolerability and safety evaluations were 
based on spontaneously reported AEs. 
Statistical Analysis
In this post-hoc subgroup analysis, the efficacy analyses 
were based on the full-analysis set population of Malaysian 
patients in the study by Fineberg et al.3 The latter consisted 
of all corresponding patients who took at least 1 dose 
of the trial medication and had at least one efficacy 
assessment, post-randomisation. The primary efficacy 
analysis comparing time-to-relapse between treatment 
groups (escitalopram versus placebo) was based on survival 
analysis methods (log-rank test and Kaplan-Meier plot). 
The hazard ratio was estimated on the basis of the Cox 
proportional hazards model. Fisher’s exact test was used to 
compare the proportions of relapsed patients.
Results
Patient Disposition at Baseline
In Malaysia, 47 patients were treated (APTS I, took at least 
1 dose of study medication) in the open-label period (Figure 
2). Of these, 10 patients withdrew and 37 completed the 
open-label treatment. The reasons for withdrawal were: 
withdrawal of consent (7), AEs (1), protocol violation (1), 
and loss to follow-up (1). More men than women (30 vs. 17) 
participated in Malaysia, whereas in the study as a whole 
Patients randomised (n = 34)
Patients completed (n = 18)Patients completed (n = 9)
Withdrawn due to lack of efficacy
(n = 2)
Withdrawn due to lack of efficacy
(n = 5)
Escitalopram (n = 20)Placebo (n = 14)
Patients treated (n = 47)
Patients completed open-label period (n = 37)
Withdrawn (n = 3)
Randomisation
16-week open-
label period
Baseline
24-week double-
blind period
Figure 2. Patient disposition for the open-label period and the randomised double-blind period of the study.
Withdrawn (n = 10)
Adverse events (1)
Withdrawal of consent (7)
Protocol violation (1)
Lost to follow-up (1)
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there were approximately equal numbers of both genders. 
Their mean age was 35 years and all were classified as 
‘Asian’. The mean body mass index of patients from 
Malaysia was lower than that of the overall cohort (21 vs. 24 
kg/m2), reflective of differences in ethnicity. The majority of 
Malaysian patients had experienced the current level of OCD 
symptoms for 2 to 5 years, with onset of symptoms ranging 
from 1 to 40 years old. At baseline, 28 (57%) patients were 
currently employed, and 2 (4%) had taken sick leave within 
the previous 3 months. Their mean Y-BOCS total score at 
baseline was 26.3, representing moderate-to-severe OCD, 
which was in line with a baseline total Y-BOCS score of 
26.4 for the whole study population.
Patient Disposition at Randomisation
Thirty four of the 37 patients who completed the open-
label period were randomised to double-blind treatment, 
20 to escitalopram and 14 to placebo. Of the 20 patients 
randomised to escitalopram, 18 completed the course and 2 
withdrew (both due to lack of efficacy). Of the 14 patients 
randomised to placebo, 9 completed the course and 5 
withdrew (all due to lack of efficacy).
 In the escitalopram group, 12 patients were men, 
and 8 were women (Table 1), as opposed to 10 men and 
4 women receiving placebo. The mean age of patients 
randomised to escitalopram was 34 years, and 39 years for 
those randomised to placebo. At randomisation, 50% and 
79% of the patients randomised to escitalopram and placebo 
respectively were currently employed. In the double-blind 
period, 17 of the 20 patients in the escitalopram group 
received 20 mg/day.
Efficacy
The primary efficacy analysis suggested a treatment 
difference in favour of escitalopram for the time to relapse of 
OCD (Figure 3, log-rank test, p = 0.07). A higher proportion 
of patients taking placebo treatment relapsed (5/14; 36% 
versus 2/20, 10%) [Fisher’s exact test, 2-sided; p = 0.10]. 
The Cox proportional hazards model gave an estimated 
hazard ratio of 4.06 (p = 0.09). Thus, the risk of relapse for 
those treated with placebo appeared to be 4 times that of 
those treated with escitalopram.
 During the open-label period, the mean Y-BOCS 
total score for the Malaysian patients decreased from 
26.3 at baseline to 11.7 at week 16, which amounts to a 
clinically relevant decrease of 14.6 points (Table 2). During 
the double-blind period, the mean change in total Y-BOCS 
score from the start of double-blind treatment (week 16) to 
Baseline (week 0)
(n = 47)
Randomisation (week 16)
Placebo (n = 14) Escitalopram (n = 20)
Sex
Men 30 (64) 10 (71) 12 (60)
Women 17 (36) 4 (29) 8 (40)
Mean age (years) 35 ± 11 39 ± 10 34 ± 14
Body mass index (kg/m2) 21 ± 4 22 ± 4 21 ± 5
Age at onset (years) 25 ± 11 27 ± 13 24 ± 12
Currently working 27 (57) 11 (79) 10 (50)
* Values are shown as Number (%), or mean ± standard deviation.
Table 1. Patient demographics at baseline (week 0) and at randomisation (week 16).*
Mean Standard deviation Mean Standard deviation
Open-label period (n = 47)
Week 0 - - 26.3 3.6
Week 2 - - 23.1 4.7
Week 4 - - 19.4 5.5
Week 8 - - 15.1 5.6
Week 16 - - 11.7 6.4
Double-blind period Placebo (n = 14) Escitalopram (n = 20)
Week 16 10.4 4.5 9.2 4.5
Week 18 10.9 4.3 9.4 4.9
Week 20 12.0 6.4 9.1 4.5
Week 24 11.9 6.4 8.3 4.4
Week 32 11.6 7.5 9.1 5.3
Week 40 12.2 7.7 8.4 5.6
Table 2. Yale-Brown Obsessive Compulsive Scale total scores (last observation carried forward).
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week 40 entailed a worsening of 1.9 in the placebo group 
and an improvement of 0.9 in those taking escitalopram, but 
this difference was not statistically significant.
 The proportion of remitters (defined as a total Y-BOCS 
score ≤ 10) during the double-blind period decreased in the 
placebo group (from 64% at week 16 to 57% at week 40). 
In the escitalopram group, the percentage increased (from 
65% at week 16 to 70% at week 40).
Safety
In the open-label period, 22 (47%) of the patients reported 
36 AEs; the majority being mild to moderate, and none were 
serious. One patient withdrew due to mild throat tightness. 
The AEs with the highest incidence were lethargy and 
nausea (both reported by 5 patients).
 In the double-blind period, 2 (14%) patients in the 
placebo group reported dizziness, which was termed a 
treatment-emergent adverse event (TEAE). Two (10%) 
patients in the escitalopram group reported 5 TEAEs (delayed 
ejaculation, dizziness, fall, hypertension, laceration), all of 
which were considered to be mild. There were no serious 
AEs, and no patients withdrew due to AEs.
Discussion
To our knowledge, this is the first publication to investigate 
the use of an escitalopram in Malaysian patients with OCD. 
It is recognised that the responses to drugs often show wide 
inter-individual variations. One of the major causes being 
genetic polymorphism of drug-metabolising enzymes in 
the liver.6 The enzymes primarily involved in escitalopram 
metabolism are the cytochrome P450 isozymes: CYP2C19, 
CYP2D6, and CYP3A4.7 The incidence of CYP2C19 
poor metaboliser phenotype is markedly higher among 
Asian populations (13-23%) than in Caucasians (2-5%),8 
and Yin et al9 have previously postulated a correlation 
between CYP2C19 polymorphism and the clinical AEs of 
citalopram (of which escitalopram is its S-enantiomer and 
main pharmacologically active agent).
 The results of this subgroup analysis suggest that 
escitalopram is well tolerated in Malaysian patients with 
OCD. No serious AEs were reported throughout the study. 
Though one patient withdrew due to an adverse event 
(throat tightness), it was classified as mild. The proportion 
of patients experiencing TEAEs was comparable in the 
escitalopram and placebo groups, both during the double-
blind period (10% vs. 14%), and throughout the study. 
No safety issues were reported among Malaysian patients 
outside the expected and known side-effects of escitalopram. 
These findings are of interest, given the evidence of a higher 
incidence of CYP2C19 poor metaboliser phenotypes among 
Asians. However, our sample size may have been too small 
to yield broad generalisations about the safety profile of 
escitalopram among Malaysian patients, vis-a-vis other 
0 4 8 12 16 20 24
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Time (weeks)
Ka
pla
n-
M
eie
r e
sti
ma
te
Escitalopram
Figure 3. Kaplan-Meier absence of relapse curves over 24 weeks for Malaysian patients. While a statistically 
significant difference between groups was not attained (p = 0.07, log rank), the analysis suggested a difference in 
favour of escitalopram for time to relapse of obsessive-compulsive disorder.
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ethnic populations.
 Consistent with the results of the main analysis,3 this 
subgroup showed an advantage for escitalopram treatment 
over placebo in terms of time to relapse as well as other 
efficacy variables. Given the relatively small sample size 
relative to the main study, the primary analysis of this subset 
showed significance at the 10% level only (p = 0.07, log-
rank test). This was hardly surprising, considering that a 
subgroup analysis did not have the same statistical power as 
the main analysis.
 For several reasons, caution should be exercised 
in interpreting these results. First, all Malaysians were 
categorised as “Asian” in ethnicity; however, Malaysia is 
a multi-ethnic country, comprising of Malays, Chinese, and 
Indians. Second, serum drug level measurements were not 
carried out, and therefore, the correlation between clinical 
response and ethnicity cannot be confirmed. In conclusion, 
this post-hoc subgroup analysis suggests that escitalopram 
is well tolerated in Malaysian patients with OCD and 
appears to confer an advantage over placebo in terms of 
time to relapse and other efficacy variables. Larger studies 
are needed to substantiate these findings.
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